Want to see MMED full AI Analyst Report?
Top Page
MiniMed Group, Inc.
(NASDAQ:MMED)
Select Model
Select Model
Rating:52Neutral
Price Target:
$15.50
▲(7.34% Upside)
Action:N/A
Date:07/05/26
The score is primarily held back by weak financial performance, driven by widening losses and a significant cash-flow reversal with worsening free cash flow. Technical indicators are supportive (price above key moving averages with positive MACD), but valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Revenue Growth
Revenue surged 104.9% in 2026, indicating strong product adoption and rapid market penetration. Durable top-line momentum supports scale economics, funds continued R&D and commercialization, and provides the foundation for potential margin expansion if the company improves cost conversion.
Negative Factors
Widening Net Losses
Net losses expanding to -$331M in 2026 show the company has yet to translate revenue growth into profitability. Persistent large losses can erode capital, limit reinvestment capacity, and increase dependence on external funding, raising long‑term dilution and execution risk if margins do not improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue surged 104.9% in 2026, indicating strong product adoption and rapid market penetration. Durable top-line momentum supports scale economics, funds continued R&D and commercialization, and provides the foundation for potential margin expansion if the company improves cost conversion.
Read all positive factors
MiniMed Group, Inc. (MMED) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.29B
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)0.23
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
EmployeesN/A
SectorGeneral
Sector StrengthN/A
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding280,842,830
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)0.94
Price to Sales (P/S)1.09
P/FCF Ratio-8.06
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.69
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda180.92
Forecast
1Y Price Target
$21.40Price Target Upside48.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MiniMed Group, Inc. Business Overview & Revenue Model
Company Description
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, c...
MiniMed Group, Inc. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | Apr 2026 | Apr 2025 | Apr 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 3.10B | 2.71B | 2.47B |
| Gross Profit | 1.68B | 1.52B | 1.44B |
| EBITDA | 49.00M | 107.00M | 59.00M |
| Net Income | -331.00M | -250.00M | -112.00M |
Balance Sheet | |||
| Total Assets | 4.63B | 4.20B | 4.09B |
| Cash, Cash Equivalents and Short-Term Investments | 298.00M | 11.00M | 54.00M |
| Total Debt | 145.00M | 11.00M | 8.00M |
| Total Liabilities | 1.02B | 870.00M | 646.00M |
| Stockholders Equity | 3.61B | 3.33B | 3.45B |
Cash Flow | |||
| Free Cash Flow | -420.00M | -53.00M | -107.00M |
| Operating Cash Flow | -197.00M | 140.00M | 41.00M |
| Investing Cash Flow | -233.00M | -193.00M | -157.00M |
| Financing Cash Flow | 716.00M | 10.00M | 112.00M |
MiniMed Group, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $3.29B | 26.47 | 11.68% | 1.80% | 11.40% | 13.96% | |
77 Outperform | $2.02B | 20.04 | 9.34% | ― | 19.55% | 21.54% | |
69 Neutral | $2.11B | 7.66 | 241.47% | ― | 20.49% | 4335.46% | |
63 Neutral | $3.39B | 16.74 | 15.28% | ― | 9.30% | 2.24% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | $4.29B | -13.46 | -9.34% | ― | ― | ― | |
52 Neutral | $3.44B | -16.81 | 9999.00% | ― | -0.36% | 16.69% |
* General Sector Average
MMED
MiniMed Group, Inc.
15.29
-3.20
-17.31%
ADUS
Addus Homecare
108.21
-3.54
-3.17%
OPCH
Option Care Health
21.57
-9.11
-29.69%
BKD
Brookdale Senior Living
14.41
6.46
81.26%
NHC
National Healthcare
210.38
108.96
107.43%
AVAH
Aveanna Healthcare Holdings
9.70
5.63
138.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.